Date: 2015-01-00
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Roche (Switzerland)
Product: RG7345/RO6926496
Action
mechanism: monoclonal antibody. RG7345 is a humanized monoclonal antibody targeting the tau phosphoepitope pS422.
Disease: Alzheimer\'s disease
Therapeutic area: Neurodegenerative diseases
Country: UK
Trial
details: This single center, randomized, investigator/subject blind, single ascending dose, placebo-controlled, parallel study will evaluate the safety, tolerability and pharmacokinetics of RO6926496 in healthy male participants. The dose escalation is adaptive in nature. It is planned to enroll 48 subjects in 6 cohorts. The anticipated total duration of the study is 16 weeks. (NCT02281786)
Latest news:
